| Name | Title | Contact Details |
|---|---|---|
Kevin Burns |
Chief Information Officer/Director of Information Technology | Profile |
The American Society of Anesthesiologists is an educational, research and scientific association of physicians organized to raise the standards of the medical practice of anesthesiology and to improve patient care.
Diversified Portfolio Biotechnology is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Altruista Health provides a suite of technology solutions that support collaborative, data-driven and person-centered approaches to population health management. Founded in 2007, Altruista Health has been recognized by Gartner as one of the fastest-growing care management technology companies serving complex care populations. Today, our solutions remove barriers to care, reduce avoidable healthcare expenses and improve health outcomes for more than 38 million people. Our GuidingCare™ platform is a web-based population health management system that enables health plans to maximize the value of their data and improve the quality of care for high-risk members. GuidingCare integrates data from a variety of systems, including medical and pharmacy claims, EMR/EHR, eligibility, HIEs and others, to power role-optimized workflow management tools for care coordination, quality improvement, care transitions management, utilization management, LTC/long term support services and more.
Armo Biosciences is a company based out of 1630 Channing Ave, Palo Alto, California, United States.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.